To evaluate denosumab’s clinical anti-myeloma activity, a proof-of-concept phase 2 multicenter single-arm study in patients with relapsed or plateau-phase myeloma investigated whether RANKL inhibition could reduce serum monoclonal protein levels. The gene discussed is TNFSF11; the disease is plasma cell myeloma.